Crinetics Pharmaceuticals, Inc.

NasdaqGS:CRNX 주식 보고서

시가총액: US$3.3b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Crinetics Pharmaceuticals 관리

관리 기준 확인 3/4

Crinetics Pharmaceuticals' CEO는 R. Struthers, Dec2008 에 임명되었습니다 의 임기는 15.5 년입니다. 총 연간 보상은 $ 5.75M, 10.7% 로 구성됩니다. 10.7% 급여 및 89.3% 보너스(회사 주식 및 옵션 포함). 는 $ 45.24M 가치에 해당하는 회사 주식의 1.3% 직접 소유합니다. 45.24M. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 3.8 년입니다.

주요 정보

R. Struthers

최고 경영자

US$5.7m

총 보상

CEO 급여 비율10.7%
CEO 임기15.5yrs
CEO 소유권1.3%
경영진 평균 재임 기간2.8yrs
이사회 평균 재임 기간3.8yrs

최근 관리 업데이트

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Jun 01
Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Recent updates

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Jun 01
Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

May 23

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Feb 29

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Nov 28
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Aug 08
Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Dec 31
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Sep 14
Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M

Aug 12

We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

Jun 15
We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point

Jun 13

Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes Progress

Apr 24

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Jan 19
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

CEO 보상 분석

R. Struthers 의 보수는 Crinetics Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$235m

Dec 31 2023US$6mUS$614k

-US$215m

Sep 30 2023n/an/a

-US$199m

Jun 30 2023n/an/a

-US$184m

Mar 31 2023n/an/a

-US$175m

Dec 31 2022US$6mUS$590k

-US$164m

Sep 30 2022n/an/a

-US$150m

Jun 30 2022n/an/a

-US$136m

Mar 31 2022n/an/a

-US$119m

Dec 31 2021US$4mUS$567k

-US$108m

Sep 30 2021n/an/a

-US$98m

Jun 30 2021n/an/a

-US$89m

Mar 31 2021n/an/a

-US$79m

Dec 31 2020US$4mUS$544k

-US$74m

Sep 30 2020n/an/a

-US$67m

Jun 30 2020n/an/a

-US$63m

Mar 31 2020n/an/a

-US$59m

Dec 31 2019US$4mUS$542k

-US$50m

Sep 30 2019n/an/a

-US$44m

Jun 30 2019n/an/a

-US$38m

Mar 31 2019n/an/a

-US$31m

Dec 31 2018US$3mUS$410k

-US$27m

Sep 30 2018n/an/a

-US$21m

Jun 30 2018n/an/a

-US$16m

Mar 31 2018n/an/a

-US$12m

Dec 31 2017US$385kUS$350k

-US$9m

보상 대 시장: R. 의 총 보상 ($USD 5.75M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 6.80M ).

보상과 수익: 회사가 수익성이 없는 동안 R. 의 보상이 증가했습니다.

CEO

R. Struthers (61 yo)

15.5yrs

테뉴어

US$5,747,994

보상

Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in November 2008 and serves as its Chief Executive Officer and President since December 2008. He is Chairman at Radionetics Oncology, I...

리더십 팀

이름위치테뉴어보상소유권
R. Struthers
Founder15.5yrsUS$5.75m1.3%
$ 43.1m
Stephen Betz
Founder & Chief Scientific Officer2.7yrsUS$2.50m0.044%
$ 1.5m
Marc J. Wilson
Chief Financial Officer6.4yrsUS$2.51m0.073%
$ 2.4m
Jeff Knight
Chief Operating Officer2.8yrsUS$2.36m0.0063%
$ 210.3k
Alan Krasner
Chief Endocrinologist6yrsUS$2.16m0.017%
$ 549.3k
James Hassard
Chief Commercial Officer2.3yrsUS$1.71m0.0022%
$ 74.2k
Garlan Adams
General Counsel & Corporate Secretary3yrs데이터 없음데이터 없음
Adriana Cabre
Chief Human Resources Officer4.1yrs데이터 없음데이터 없음
Kevin Capps
Head of Intellectual Propertyno data데이터 없음데이터 없음
Chris Robillard
Chief Business Officer2.3yrs데이터 없음데이터 없음
Dana Pizzuti
Chief Medical & Development Officer1.8yrsUS$3.61m0.0018%
$ 59.6k
Robert Cuddihy
Senior Vice President of Medical Affairsless than a year데이터 없음데이터 없음

2.8yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: CRNX 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
R. Struthers
Founder15.6yrsUS$5.75m1.3%
$ 43.1m
Wendell Wierenga
Independent Chairman of the Board8.7yrsUS$375.31k0.13%
$ 4.5m
Matthew Fust
Independent Director6.3yrsUS$348.56k0.024%
$ 782.2k
Camille Bedrosian
Independent Director3.8yrsUS$339.56k0.0076%
$ 253.2k
Rogerio Vivaldi Coelho
Independent Director2.4yrsUS$338.56k0.014%
$ 464.1k
Weston Nichols
Independent Director6.3yrsUS$338.56k0.0076%
$ 253.2k
Stephanie Okey
Independent Director4.9yrsUS$342.31k0.0076%
$ 253.2k
Caren Deardorf
Independent Director2.3yrsUS$330.06k0.0076%
$ 253.2k
Martin Heinrich Reincke
Member of Scientific Advisory Board2.2yrs데이터 없음데이터 없음
John Newell-Price
Member of Scientific Advisory Board2.2yrs데이터 없음데이터 없음
William Young
Member of Scientific Advisory Board2.2yrs데이터 없음데이터 없음

3.8yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: CRNX 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.